MX9205240A - Composicion y metodo para tratar hepatitis c. - Google Patents

Composicion y metodo para tratar hepatitis c.

Info

Publication number
MX9205240A
MX9205240A MX9205240A MX9205240A MX9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A
Authority
MX
Mexico
Prior art keywords
composition
treating hepatitis
thymosins
alone
compositions
Prior art date
Application number
MX9205240A
Other languages
English (en)
Spanish (es)
Inventor
Paul Chretien
Milton Mutchnick
Original Assignee
Paul Chretien
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Chretien, Milton Mutchnick filed Critical Paul Chretien
Publication of MX9205240A publication Critical patent/MX9205240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
MX9205240A 1991-09-13 1992-09-14 Composicion y metodo para tratar hepatitis c. MX9205240A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
MX9205240A true MX9205240A (es) 1993-07-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205240A MX9205240A (es) 1991-09-13 1992-09-14 Composicion y metodo para tratar hepatitis c.

Country Status (23)

Country Link
US (3) US6001799A (enExample)
EP (1) EP0603305B1 (enExample)
JP (1) JP3228512B2 (enExample)
KR (1) KR100254082B1 (enExample)
AT (1) ATE152914T1 (enExample)
AU (1) AU667327B2 (enExample)
CA (1) CA2119006C (enExample)
CZ (1) CZ286827B6 (enExample)
DE (1) DE69219782T2 (enExample)
DK (1) DK0603305T3 (enExample)
ES (1) ES2103966T3 (enExample)
FI (1) FI107879B (enExample)
GR (1) GR3024025T3 (enExample)
HK (1) HK1021687A1 (enExample)
HU (1) HU221006B1 (enExample)
MX (1) MX9205240A (enExample)
NO (1) NO941310D0 (enExample)
RO (1) RO111991B1 (enExample)
RU (1) RU2104010C1 (enExample)
SG (1) SG64897A1 (enExample)
TW (1) TW224053B (enExample)
WO (1) WO1993005806A1 (enExample)
ZA (1) ZA926964B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
EP0728010A4 (en) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals METHOD FOR TREATING HEPATITIS B CARRIERS WITH A MINOR DISEASE
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (enExample) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
ES2194860T3 (es) * 1993-11-05 2003-12-01 Sciclone Pharmaceuticals Inc Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
PT886527E (pt) * 1996-02-28 2001-12-28 Unihart Corp Composicao farmaceutica que incorpora o interferao alfa humano natural
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
EA007785B1 (ru) * 2000-08-07 2007-02-27 Сайклоун Фармасьютикалз, Инк. Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AR036727A1 (es) * 2001-10-05 2004-09-29 Intermune Inc Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento
JP2005506997A (ja) * 2001-10-26 2005-03-10 ロード・アイランド・ホスピタル 遺伝的免疫化のチモシン増強
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US20040002476A1 (en) * 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
JP5116972B2 (ja) 2002-12-12 2013-01-09 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドの製造方法
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
BRPI0412849A (pt) * 2003-07-25 2006-09-26 Idenix Cayman Ltd compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2769377T3 (es) 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
WO2007128647A1 (en) * 2006-05-02 2007-11-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010042697A1 (en) * 2008-10-08 2010-04-15 University Of Miami Regulation of lymphocytes and uses therefor
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
ES2537785T3 (es) 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
FI941133L (fi) 1994-03-10
US20070218033A1 (en) 2007-09-20
RO111991B1 (ro) 1997-04-30
NO941310L (no) 1994-04-12
TW224053B (enExample) 1994-05-21
AU2644792A (en) 1993-04-27
KR100254082B1 (ko) 2000-09-01
US6001799A (en) 1999-12-14
ES2103966T3 (es) 1997-10-01
HU221006B1 (hu) 2002-07-29
RU2104010C1 (ru) 1998-02-10
FI107879B (fi) 2001-10-31
GR3024025T3 (en) 1997-10-31
DE69219782T2 (de) 1997-10-09
DK0603305T3 (da) 1997-09-01
WO1993005806A1 (en) 1993-04-01
CA2119006A1 (en) 1993-04-01
HU9400758D0 (en) 1994-06-28
RU94022480A (ru) 1996-07-20
NO941310D0 (no) 1994-04-12
SG64897A1 (en) 1999-05-25
ZA926964B (en) 1993-04-26
CZ286827B6 (cs) 2000-07-12
CZ55194A3 (en) 1994-10-19
EP0603305A1 (en) 1994-06-29
FI941133A0 (fi) 1994-03-10
JPH06510998A (ja) 1994-12-08
US5849696A (en) 1998-12-15
CA2119006C (en) 2005-08-23
EP0603305B1 (en) 1997-05-14
JP3228512B2 (ja) 2001-11-12
HK1021687A1 (en) 2000-06-23
ATE152914T1 (de) 1997-05-15
HUT75166A (en) 1997-04-28
DE69219782D1 (de) 1997-06-19
AU667327B2 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
ATA839575A (de) Ein- oder mehrteiliges, insbesondere keramisches implantat
MX9304209A (es) Composicion y metodo de tratamiento de hepatitis b.
BR9105737A (pt) Processo para reduzir a contaminacao de um produto de amplificacao,conjunto para uso em um tipo de procedimento de amplificacao e processo para amplificar uma sequencia de amplificacao de uma sequencia-alvo
DK0574457T3 (da) Antiviral nucleosidkombination
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
DK282585A (da) Synergistiske blandinger af interferoner og tumor-nekrose-faktor
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
DK486588A (da) Konjungater af cytokininer med immunglobuliner
FI951538A7 (fi) Parannettu fysikaaliset ominaisuudet omaavat koostumukset, esineet ja menetelmät hapen poistamiseksi
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
DK214889A (da) Ikke-vandigt, ikke-ionisk, kraftigt virkende vaskemiddel med forbedret stabilitet under anvendelse af mikrokugler og/eller vicinal-hydroxyforbindelser
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ES2120962T3 (es) Composicion antivirica.
AU6169298A (en) Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combinationtherapy for treating hepatitis virus infections
NO890046D0 (no) Disubstituerte pyridiner.
GT198301619A (es) Interferon inmune humano homogeneo y procedimiento para el mismo.
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES2036526T3 (es) Composiciones de interferon.
DE69331977D1 (de) Löslicher LDL-Rezeptor, seine Herstellung und Verwendung
NO984760D0 (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
DE68900760D1 (de) Virushemmende nukleosidmischung.
MX9302578A (es) Agentes antivirales.

Legal Events

Date Code Title Description
FG Grant or registration
MK Ceased due to expiration of term